Bioo Therapeutics, a division of Bioo Scientific, said this month that it has signed a collaborative research agreement with Texas Tech University researcher Premlata Shankar to develop methods to deliver siRNAs into T cells.

Under the deal, Shankar will use Bioo's Targeted Transport Technology, which involves joining a carrier agent to a monoclonal antibody to produce a conjugate that is then loaded with an RNAi molecule such as an siRNA or miRNA mimic, to deliver anti-HIV siRNAs into T cells.

Specific terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.